Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Organisation › Details

Merus (Group)

Merus is a Dutch biotechnology company developing cancer therapeutics based on human bispecific antibodies. Merus’ bispecific antibodies have the robust and proven full-length IgG format, they are manufactured using industry standard processes and have predictable in vivo behavior such as long half-life and low immunogenicity. Merus has two lead programs in development, MCLA-128 for the treatment of HER2 expressing solid tumors, and MCLA-117 for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company is also developing a broad pipeline of preclinical programs in immuno-oncology using its unique technology platforms. *

 

Period Start 2006-01-17 existent
  Today Merus B.V.
Product Industry  MeMo™ humanized mouse antibody platform
     
Region Region Utrecht
  Country Netherlands
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 1,977,000 (revenue (2015) 2015-12-31)
  Profit -23,184,000 (2015-12-31)
  Cash 32,851,000 (2015-12-31)
     
    * Document for �About Section�: Selexis S.A.. (5/20/15). "Press Release: Merus and Selexis Receive a €2.1 Million Grant for Single Cell Line Manufacturing of a Bispecific Antibody Combination to Treat Colorectal Cancer". Geneva.
     
   
Record changed: 2018-10-31

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Merus (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top